# Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

> **NCT04848272** · PHASE1 · UNKNOWN · sponsor: **St Vincent's Institute of Medical Research** · enrollment: 48 (estimated)

## Conditions studied

- Lung Injury

## Interventions

- **DRUG:** Lanadelumab
- **OTHER:** Saline control

## Key facts

- **NCT ID:** NCT04848272
- **Lead sponsor:** St Vincent's Institute of Medical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-09
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04848272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04848272, "Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04848272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*